In a clinical trial using genetically modified fibroblasts secreting NGF injected into the basal forebrain in AD patients, Tuszynski et al. (2005) demonstrated the feasibility of an ex vivo gene therapy approach with results indicating a slowing of disease progression. Here, NGF is linked to Alzheimer disease.